4 things to know about VolitionRX’s CRC blood test system & its sale in the US

VolitionRX, a developer of blood tests that can predict colon cancer, is looking to start selling the blood test system in the United States in the next year or so, according to a Benzinga report.

Advertisement
By: Staff

Here are four things to know:

1. VolitionRX’s system works by collecting a blood sample from a patient.

2. The sample is analyzed for cancer specific nucleosome patterns and structures.

3. The company has been awarded numerous patents for the detection of nucleosomes.

4. VolitionRX has been approved to start selling the product in Europe.

More articles on GI/endoscopy:
Innovative colorectal cancer screening methods for remote areas
FDA clears 5 GI/endoscopy devices in December
US Endoscopy acquires Bracco Diagnostics’ GI business unit

How top hospitals are turning denials into ROI: 10 strategies

Recommended Whitepaper

Advertisement

Next Up in GI & Endoscopy

  • GIs sound the alarm on CMS payment changes

    Gastroenterologists are raising concerns about the CMS’ finalized payment policies, according to a joint statement from the American College of…

    By: Patsy Newitt

  • The new frontiers in GI care

    As gastroenterology evolves, leaders are reimagining how to deliver comprehensive, patient-centered care.  Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland…

    By: Patsy Newitt
Advertisement

Comments are closed.